I just paid an almost embarrassing price for a cup of Ethiopian coffee, the first I have ever tasted, and better than the coffee of my ordinary mornings. It was bright, floral, almost tea-like, with a sweetness that lingered long after the cup was empty. Ethiopia is where coffee began, the birthplace of arabica, so I assumed a large share of what I paid for the coffee went back to the hillsides where it grew. It turns out that is not the case.
The great fortune in coffee does not live in Ethiopia, or anywhere else coffee grows. It lives in a country where not a single commercial coffee tree stands.
Switzerland, a nation of roughly 9 million people wedged between the Alps and the Jura, is one of the five largest coffee exporters on Earth. It shipped about $4.2 billion of coffee in 2025, more than Ethiopia, the birthplace of arabica, and more than Uganda, Kenya, and Tanzania combined. Coffee is now Switzerland’s single most important agricultural export, ahead of the cheese and chocolate that fill its postcards. Six of the world’s most important coffee traders are headquartered there, and more than half of all globally traded coffee passes through Swiss hands.
Africa, by contrast, is home to 1.5 billion people, 54 nations, and a landmass on which Switzerland would vanish like a coffee stain on a tablecloth. Yet until recently, the entire continent of Africa earned little more from coffee exports than the Swiss did, and in some years less. That changed in 2025. As Arabica prices hit historic highs and global coffee export values nearly doubled from their 2021 level, Africa’s share, about 9 percent, clearly surpassed Switzerland’s in gross dollars. But if you look at the price per ton, Switzerland still dominates. Swiss coffee left the country at an average of $37,694 per ton in 2025, Ethiopian coffee at $7,007, and Ugandan coffee at $5,897.
Why? Because the same bean is five to six times more valuable once it has been roasted, ground, sealed into an aluminum capsule, and stamped with a name like Nespresso. The Swiss import green beans at a few francs a kilo and export them at many times that. In other words, Africa sells the harvest, but Switzerland sells the transformation. In coffee, the great profits are not made where the cherry ripens, but where the value is added: the roastery, the capsule line, the brand, the machine, the trading desk in Geneva that prices the whole world’s supply.
Philadelphia lives inside a version of a similar paradox. My city grows some of the finest scientific coffee on the planet, but, too often, we ship it out green.
Grown in Philadelphia, Roasted in Cambridge
The most consequential scientific coffee bean Philadelphia ever grew was a molecule. In 2005, Katalin Karikó and Drew Weissman, working in modest Penn laboratories and often on the margins of grant funding, showed that a small chemical substitution in messenger RNA allowed it to slip past the body’s alarm system and deliver its instructions. This scientific breakthrough went largely unheralded in Philadelphia for years because quiet, patient, and unglamorous science never makes headlines in my city. Thankfully, eighteen years later, in 2023, this science earned Karikó and Weissman the Nobel Prize in Physiology or Medicine.
READ: The Review by Ajay Raju | Cultivating farmers, not the seeds: Germination Project’s 50-year bet on Philadelphia (October 5, 2026)
Between those two dates, a young Harvard-affiliated stem cell scientist named Derrick Rossi read their paper, and the venture firm Flagship Pioneering in Cambridge helped turn that reading into Moderna in 2010. In Mainz, Germany, a husband-and-wife team built BioNTech, and hired Karikó herself. Penn, meanwhile, did what universities commonly did back then: it exclusively licensed the foundational patents in 2010 to a small Wisconsin company, mRNA RiboTherapeutics, which sublicensed them to its affiliate Cellscript. The bean was sold green.
Then, in 2020, the pandemic arrived, and the roasteries fired up. Pfizer’s Comirnaty, co-developed with BioNTech, sold $36.8 billion in 2021, $37.8 billion in 2022, and $11.2 billion in 2023. Moderna’s Spikevax sold $17.7 billion, $18.4 billion, and $6.7 billion over the same three years. Together, roughly $129 billion in three years, from
Nobel-winning science seeded in West Philadelphia.
To be fair, Penn did not go home empty-handed. The university became the nation’s top earner of licensing revenue, and after a December 2024 settlement with BioNTech, Penn’s royalties from the Pfizer-BioNTech vaccine alone rose to at least $2 billion. That money funds science, and the inventors rightly shared in it. But set $2 billion against $129 billion and you can see the Africa-Switzerland coffee paradox: the grower’s share versus the roaster’s. The jobs, the manufacturing plants, the market capitalization, the follow-on pipelines, the talent magnet, the tax base, all of that settled in Cambridge, Mainz, and New York, not in Philadelphia.
The lost harvest is not just historical. Penn’s foundational mRNA patents begin expiring in May 2027. And in August 2025, the federal government began winding down 22 BARDA-funded mRNA vaccine projects worth about $500 million. The window in which Philadelphia could claim mRNA as an industry rather than an anecdote is slowly closing.
Meanwhile, for Boston, the pandemic was not just a crisis, but a harvest. While we claimed a Nobel Prize and a hefty royalty check, both great honors, Boston created an economy.
Where Philadelphia Stands: Fifth, and Rising, but Far from the Summit
By every serious measure, Greater Philadelphia is a top-ten American biotech cluster, and on a good year a top-five one. In its June 2026 ranking, Genetic Engineering & Biotechnology News placed Greater Philadelphia fifth nationally, the most improved region on the list, climbing two spots on the strength of higher rankings in venture funding, lab space, and NIH funding. Colliers ranked the region fourth among U.S. life sciences markets in both its 2024 and 2025 reports. CBRE reported in June 2026 that Philadelphia set a record for core life sciences employment in 2025 and kept adding jobs this year.
But rankings flatter. Standing fifth in a race where the leader runs at five times your speed is not the same as being in contention. Here is how the two regions compare in GEN’s 2026 data: $1.31 billion in VC funding compared to Boston’s $6.85 billion; 25.9 million sq ft of lab space compared to Boston’s 63.2 million sq ft; 88,000 life sciences jobs compared to Boston’s 117,100. From 2014 through 2024, the Boston area added four biotech R&D jobs for every one added in Philadelphia. In 2024, Boston employed nearly 60,000 people in biotech research and development; Philadelphia and Montgomery County together employed 13,800. Boston is home to ten institutions receiving at least $100 million a year from NIH. Philadelphia has two: Penn and CHOP.
READ: The Review by Ajay Raju | Are we watching the same game? Same news? Same debate? (September 28, 2026)
Again, to be fair, Penn and CHOP punch far above their numbers. Research at Penn has contributed to 45 FDA-approved treatments since 2013. CHOP last year treated Baby KJ Muldoon, the first patient in the world to receive a personalized CRISPR gene-editing therapy. Philadelphia is the acknowledged birthplace of modern cell and gene therapy: Carl June’s CAR-T work, Jim Wilson’s gene vectors, Kathy High’s Spark Therapeutics and Luxturna, the first FDA-approved gene therapy for an inherited disease. Our region now counts nearly 10,000 workers with cell and gene therapy expertise. This is the finest arabica in the world.
But the export pattern persists, case after case:
Capstan Therapeutics, a Penn-founded company reengineering immune cells inside the body, sold to AbbVie for up to $2.1 billion in 2025, the richest price paid for a private early-stage biotech since 2022. It was headquartered in San Diego, because investors wanted a CEO who already lived there.
Spark Therapeutics, born at CHOP, sold to Roche (a Swiss company, fittingly) for $4.8 billion in 2019. In 2025, Roche laid off more than half its Philadelphia workforce; as of December 2025, about 300 remained.
Centocor, Philadelphia’s original biotech champion, was bought by Johnson & Johnson for $4.9 billion in 1999. A drug still in its pipeline then, Stelara, became J&J’s top seller, generating $10.9 billion in 2023. Many of Centocor’s alumni, as the Philadelphia Inquirer noted, wound up building elsewhere.
Dispatch Bio, a 2025 Penn spinout, raised $216 million from Chicago and San Francisco investors. Most of its staff work here; its CEO sits in the Bay Area.
There are hopeful signs though. In November 2025, Eli Lilly chose Philadelphia as only the fourth U.S. city for a Lilly Gateway Labs incubator, after Boston, the Bay Area, and San Diego. In January 2026, Lilly announced a $3.5 billion manufacturing plant in the Lehigh Valley, Pennsylvania’s largest-ever biotech project. Now GSK, the global life sciences company, has chosen Pennsylvania once again, committing $800 million to build a new state-of-the-art facility in Montgomery County to produce medicines that patients around the world rely on. The decision keeps 4,500 GSK employees in the Commonwealth and will add 300 new jobs over the next five years. January also brought a new $50 million fund dedicated to Penn life sciences start-ups. Philadelphia-area startups across all sectors raised $1.26 billion in Q2 2026, the third straight billion-dollar quarter. The roastery is being built.
How Boston Built Its Roastery: Eighty Years of Deliberate Habit
Switzerland did not stumble into coffee. Nestlé spent most of the 1930s perfecting soluble coffee before launching Nescafé in 1938, and then decades more building the capsule empire that became Nespresso. And Boston did not stumble into biotech either. Its dominance is the compound interest of choices made across eight decades, by people who understood that science is the bean and an economy is the roast.
The story begins in 1945, when former MIT engineering dean Vannevar Bush wrote Science, the Endless Frontier and drew the blueprint for federally funded university research. A year later, in 1946, Harvard Business School professor Georges Doriot founded American Research and Development Corporation in Boston, widely regarded as the first modern venture capital firm. Boston, in other words, invented the very instrument that would later carry Philadelphia’s discoveries away. That was eighty years ago this year.
Then came a moment of civic courage that Philadelphia’s leaders should study closely. In 1976, as recombinant DNA research frightened the public, Cambridge’s mayor Alfred Vellucci held hearings on whether to ban it altogether. Instead, in 1977, the city enacted the nation’s first municipal ordinance to regulate the work safely. What looked like restriction became certainty: companies now knew the rules. Biogen was founded in 1978 (in Geneva, Switzerland, as it happens, before planting itself in Cambridge) and Genzyme in 1981. Kendall Square, once a district of candy factories and rubber works, became the most valuable square mile in global life sciences.
Government did not merely tolerate the industry, but invested in it as a strategy that outlasted governors. In 2008, Governor Deval Patrick signed a ten-year, $1 billion Massachusetts Life Sciences Initiative for infrastructure, loans, grants, and tax incentives. Republicans renewed it. In November 2024, Governor Maura Healey signed the Mass Leads Act, reauthorizing the initiative with a $500 million capital commitment for the next decade. Three governors, two parties, one strategy.
So when Derrick Rossi read the Karikó-Weissman paper and wanted to build a company, the roastery was already running. Flagship Pioneering had the capital, the company-creation model, and the patience. Kendall Square had the lab space, the serial CEOs, the regulatory lawyers, the manufacturing know-how, and the investors who meet each other in line for coffee. Moderna’s market value went from a few billion dollars before the pandemic to roughly $190 billion at its 2021 peak. As a result, for Boston, COVID-19 was not just a crisis to survive, but the harvest their eighty-year planting had been waiting for.
Boston’s model is not invulnerable. Its own exuberance overbuilt the roastery: lab availability reached 32.7 percent in early 2026, and layoffs at Takeda and others have stung. But even in a downturn, Boston raised more than five times Philadelphia’s life sciences venture capital in 2025, a reminder that a wounded giant remains a giant.
Learning to Roast: What Philadelphia Needs to Become Top Tier
Penn’s chief innovation officer, John Swartley, put the diagnosis in a single sentence to the Inquirer: great science is just one ingredient; the region also needs capital, experienced leadership, real estate and manufacturing infrastructure, and strong city and state support. Every item on that list is a stage of roasting.
Here is what each would take:
Capital at the scale of ambition. Boston’s life sciences venture haul in 2025 exceeded Philadelphia’s by more than $5.5 billion. No single policy will close that gap, but the public sector can change the odds. Pennsylvania’s new $125 million Innovate in PA 2.0, signed into the 2026-27 budget, is the state’s most significant life sciences commitment in nearly three decades, and it deserves applause. But it is one-eighth of what Massachusetts committed in 2008, and is spread across several sectors, not life sciences alone. Pennsylvania should treat this $125 million as a down payment on a decade-long, bipartisan, billion-dollar compact, insulated from the budget cycle the way Massachusetts insulated its own. Our region’s universities, health systems, foundations, and family offices, which collectively steward tens of billions of dollars, should commit a meaningful share to evergreen local growth funds, learning from the disappointments of the Quaker BioVentures era rather than retreating from them.
A bench of builders, not just inventors. The single most repeated explanation for why companies leave is the absence of experienced biotech CEOs who live here. Capstan went to San Diego and Dispatch’s chief executive sits in the Bay Area for that reason. Philadelphia must recruit and retain operators the way it recruits surgeons: CEO-in-residence programs funded by Penn, CHOP, Jefferson, and the venture community; board seats for Centocor and Spark alumni; and deliberate effort to give the next generation of local executives their first company. Talent pools are self-reinforcing. In Boston, if a startup fails, there is another one down the street. We need that street.
Keep the bean until it is roasted. Penn has already moved from licensing its discoveries to distant companies toward actively creating them, a crucial shift. The next step is to make local formation the default rather than the exception: licensing terms, institutional co-investment, and lab access structured to reward companies that keep headquarters, leadership, and manufacturing in the region. Penn’s foundational mRNA patents begin expiring in 2027; the next platform must not be sold green.
Own the manufacturing. Swiss coffee wealth lives in the roasting plant and the capsule line. Biotech wealth increasingly lives in manufacturing, especially for cell and gene therapies, where the process is the product. The region has real assets: Lilly’s $3.5 billion Lehigh Valley plant, Spark’s $575 million Gene Therapy Innovation Center, a $450 million TerraPower radioisotope facility at the Bellwether District, contract manufacturers in King of Prussia, and the Navy Yard. A coordinated regional manufacturing strategy, with a trained workforce from our community colleges and trade unions, would turn these from isolated wins into a cluster.
READ: The Review by Ajay Raju | Our dollar, your problem (September 14, 2026)
Diversify the harvest. The Inquirer notes that Philadelphia’s specialty, cell and gene therapy, is a relatively small segment whose allure to investors has faded. A great coffee nation does not grow one varietal. Philadelphia’s next frontiers are already visible in its own labs: mRNA beyond vaccines, including the cancer vaccine Penn helped test in a successful late-stage trial this September; in vivo cell engineering for autoimmune disease, the very field Capstan pioneered; CRISPR therapies of the kind CHOP delivered to Baby KJ; and AI-enabled drug discovery, where the region’s health-system data is an underused asset.
A hospitable government and business culture. Boston turned a moment of public fear in 1976 into regulatory certainty. Philadelphia must ask, honestly, whether its city wage and business taxes, permitting timelines, and civic tone signal to a founder that she is wanted. Federal turbulence, from NIH cuts to the cancellation of BARDA’s mRNA portfolio, makes state and local reliability more valuable, not less. Stability is itself an incentive.
None of these ideas is novel, which is precisely the point. Boston did not win because it had secret knowledge. It won because it acted on obvious knowledge, consistently, for eighty years.
The Aroma Stays Where the Roasting Happens
Anyone who has walked past a roastery knows that the aroma of coffee does not linger on the farm, but hangs in the street outside the roaster, drawing people in, filling cafés, creating jobs and rituals and whole neighborhoods. The farmer in Ethiopia’s Sidama highlands sees the cherry turn red, but the city that roasts it smells the fortune.
Philadelphia has spent fifty years growing the world’s most remarkable scientific harvest: Centocor’s antibodies, June’s engineered T cells, Wilson’s vectors, High’s gene therapy, Karikó and Weissman’s modified messenger RNA. We have earned a Nobel, Breakthrough Prizes, and royalty checks, but Penn Medicine, not Philadelphia, is mostly responsible for these successes.
Switzerland, with no coffee trees and nine million people, shows what a small place can do when it decides that the value is in the transformation. Boston, with an eighty-year head start, shows what a place can do when it patiently invests in decades.
The next harvest is already ripening in one of our 600-plus labs in Philadelphia. I can say with confidence that Philadelphia will continue to discover the next medical breakthroughs. What is unclear is whether we will build a bigger roastery before the beans arrive.